Median Technologies (ALMDT) | Financial Analysis & Statements
Median Technologies S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
24.4M
Total Liabilities
58.3M
Shareholders Equity
-34.0M
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Median Technologies Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 22.9M | 22.2M | 23.7M | 20.5M | 13.5M |
| Cost of Goods Sold | -886.0K | -1.0M | -750.0K | 117.0K | 135.0K |
| Gross Profit | 23.8M | 23.2M | 24.4M | 20.4M | 13.3M |
| Gross Margin % | 103.9% | 104.5% | 103.2% | 99.4% | 99.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 1.3M | 739.0K | 759.0K | 421.0K | 281.0K |
| Other Operating Expenses | 18.3M | 18.5M | 17.8M | 13.3M | 9.3M |
| Total Operating Expenses | 19.6M | 19.3M | 18.6M | 13.7M | 9.6M |
| Operating Income | -22.4M | -22.9M | -23.2M | -11.4M | -8.7M |
| Operating Margin % | -97.5% | -103.0% | -97.9% | -55.7% | -64.7% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 3.8M | 1.9M | 1.3M | 1.2M | 789.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -25.1M | -22.9M | -19.7M | -18.9M | -12.8M |
| Income Tax | 144.0K | 76.0K | 521.0K | 437.0K | -8.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -25.2M | -23.0M | -20.2M | -19.3M | -12.8M |
| Net Margin % | -110.0% | -103.4% | -85.4% | -93.9% | -95.0% |
| Key Metrics | |||||
| EBITDA | -20.3M | -21.8M | -22.4M | -10.5M | -8.2M |
| EPS (Basic) | €-1.37 | €-1.25 | €-1.28 | €-1.25 | €-1.06 |
| EPS (Diluted) | €-1.37 | €-1.25 | €-1.28 | €-1.25 | €-1.06 |
| Basic Shares Outstanding | 18493782 | 18376380 | 15778248 | 15470248 | 12115224 |
| Diluted Shares Outstanding | 18493782 | 18376380 | 15778248 | 15470248 | 12115224 |
Income Statement Trend
Median Technologies Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 8.1M | 19.5M | 21.5M | 39.0M | 16.3M |
| Short-term Investments | 151.0K | 123.0K | 200.0K | 241.0K | 83.0K |
| Accounts Receivable | 7.5M | 6.6M | 6.0M | 5.0M | 4.3M |
| Inventory | 48.0K | 102.0K | 0 | 0 | 0 |
| Other Current Assets | -1.0K | - | 1.0K | -1.0K | -1.0K |
| Total Current Assets | 20.5M | 31.9M | 31.5M | 47.5M | 23.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 5.9M | 5.4M | 2.6M | 3.6M | 1.4M |
| Goodwill | 2.0M | 1.7M | 963.0K | 72.0K | 57.0K |
| Intangible Assets | 2.0M | 1.7M | 963.0K | 72.0K | 57.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | 2.0K | -1.0K | 1.0K | 2.0K |
| Total Non-Current Assets | 3.9M | 4.0M | 3.2M | 1.8M | 1.9M |
| Total Assets | 24.4M | 35.9M | 34.8M | 49.4M | 25.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.2M | 3.8M | 3.7M | 3.1M | 2.6M |
| Short-term Debt | 20.5M | 736.0K | 530.0K | 374.0K | 350.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 4.8M | 5.1M | 4.7M | 3.8M | 3.2M |
| Total Current Liabilities | 44.1M | 22.7M | 23.4M | 27.3M | 20.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 9.0M | 19.2M | 17.6M | 16.1M | 16.4M |
| Deferred Tax Liabilities | 254.0K | 225.0K | 277.0K | 241.0K | 237.0K |
| Other Non-Current Liabilities | -1.0K | 1.0K | - | -1.0K | - |
| Total Non-Current Liabilities | 14.2M | 23.5M | 18.6M | 17.2M | 16.3M |
| Total Liabilities | 58.3M | 46.2M | 42.0M | 44.4M | 36.6M |
| Equity | |||||
| Common Stock | 926.0K | 920.0K | 790.0K | 775.0K | 607.0K |
| Retained Earnings | -25.2M | -23.0M | -20.2M | -19.3M | -12.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -34.0M | -10.3M | -7.3M | 4.9M | -11.4M |
| Key Metrics | |||||
| Total Debt | 29.4M | 20.0M | 18.2M | 16.5M | 16.8M |
| Working Capital | -23.6M | 9.2M | 8.1M | 20.3M | 3.1M |
Balance Sheet Composition
Median Technologies Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -25.2M | -23.0M | -20.2M | -19.3M | -12.8M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 1.4M | 2.8M | 7.9M | 1.8M | 267.0K |
| Working Capital Changes | 0 | 0 | 0 | 0 | 0 |
| Operating Cash Flow | -20.1M | -18.5M | -10.8M | -15.9M | -11.8M |
| Investing Activities | |||||
| Capital Expenditures | -227.0K | -1.3M | -1.4M | -437.0K | -293.0K |
| Acquisitions | 0 | 0 | 0 | 0 | - |
| Investment Purchases | -86.0K | 0 | 0 | -229.0K | -26.0K |
| Investment Sales | 0 | 27.0K | 0 | 39.0K | 58.0K |
| Investing Cash Flow | -313.0K | -1.3M | -1.4M | -627.0K | -261.0K |
| Financing Activities | |||||
| Share Repurchases | - | -76.0K | -42.0K | - | -58.0K |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 8.5M | 3.2M | 0 | 0 | 15.0M |
| Debt Repayment | - | - | - | - | -360.0K |
| Financing Cash Flow | 8.6M | 21.6M | 123.0K | 33.6M | 14.6M |
| Free Cash Flow | -19.0M | -21.5M | -17.2M | -10.6M | -5.8M |
| Net Change in Cash | -11.8M | 1.8M | -12.1M | 17.0M | 2.6M |
Cash Flow Trend
Median Technologies Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.61
Forward P/E
-11.56
Price to Sales
7.91
Profitability Ratios
Profit Margin
-94.04%
Operating Margin
-81.61%
Return on Equity
74.31%
Return on Assets
-44.14%
Financial Health
Current Ratio
0.36
Debt to Equity
-1.15
Beta
0.57
Per Share Data
EPS (TTM)
€-1.16
Book Value per Share
€-2.08
Revenue per Share
€1.23
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALMDT | 188.6M | -3.61 | - | 74.31% | -94.04% | -1.15 |
| Eurobio Scientific | 229.6M | 108.64 | 1.33 | 2.24% | 2.90% | 0.19 |
| Guerbet S.A | 127.3M | 13.77 | 0.47 | -34.58% | -13.56% | 169.65 |
| Affluent Medical | 122.2M | -8.37 | 5.24 | -62.51% | -279.97% | 110.96 |
| Mauna Kea | 37.4M | -1.17 | -1.37 | 42.66% | -127.03% | -1.35 |
| Diagnostic Medical | 34.5M | -133.50 | 2.16 | -11.62% | -3.37% | 138.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.